Full Press Release Details
KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH
TO INCREASE LONGEVITY AND
HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO (" -KLOTHO")
Recent clinical and pre-clinical studies and analysis indicates
the potential to increase lifespan and reduce age-associated degeneration in multiple organ systems has be realized with a focus on the
human gene called Klotho.
NEW YORK, June 9, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:
called-alpha-klotho--klotho-302476036.html - financial-modalKLTO), a U.S.-based biogenetics company announced the findings of pre-clinical
studies indicating the potential of elevating Klotho gene expression to simultaneously reduce the age-associated degeneration in multiple
organs, increasing both life and health span.
Pioneering discoveries by Professor Makoto Kuro-O in 1997 showed that
Klotho concentrations in the blood were directly associated with lifespan of mammals - the lower the Klotho blood levels the shorter
the lifespan. Kuro-O's laboratory then published the first evidence that genetic over expression of the full-length form of Klotho in
mice, increased in lifespan of mice of up to 30%-40% longer compared to the normal mouse lifespan. Since then, the Klotho protein has
gained much attention because of its ability to influence key biological pathways involved in metabolism, inflammation and tissue repair,
which are closely linked to the aging process.
A series of experiments led by Joan Roig-Soriano and colleagues, published
in the February 2025 edition of Molecular Therapy, highlights the promising role of the naturally occurring secreted form of the Klotho
protein ("s-KL") and its effects on healthy aging mice and mice with a rapidly aging phenotype. Key observations were that,
while aging is a major risk factor for many pathologies, including cognitive decline, neuroinflammation, sarcopenia, and osteoporosis,
the secreted protein s-KL has emerged as a potentially promising therapeutic anti-aging molecule due to its many biological effects involving
multiple pathways related to cell injury, stress, and inflammation. The s-KL was administered using an adeno-associated virus serotype
9 delivery vector (AAV9) that expressed the secreted KL protein isoform and efficiently increased the concentration of s-KL in serum,
resulting in a 20% increase in lifespan.
Dr. Joseph Sinkule, the CEO of Klotho Neurosciences (KLTO) commented
that "KLTO has secured an exclusive worldwide license for s-Kl from Universitat Aut noma de Barcelona (UAB) and Instituci
Catalana de Recerca i Estudis Avan ats (ICREA) in Spain. As a result, we have the exclusive use of patents issued in the USA, Europe,
and China covering a secreted splice variant of mammalian Klotho referred to as s-KL, as a treatment for neurodegenerative and age -related
disorders. Professor Makoto Kuro-O is also a scientific advisor to KLTO. This recently published paper provides further credence to our
development of s-KL as a treatment to reduce age-associated degeneration where, as a company, KLTO has a particular focus on neurodegenerative
diseases such as ALS, Alzheimer's and Parkinson's disease. The results disclosed in the paper show the potential of elevating s-KL protein
expression, resulting in the reduction of age-associated degeneration in multiple organs, increasing both life and health span".
About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ:
KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived
from a patented form of the "anti-aging" human Klotho gene (s-KL), and it's novel delivery systems to transform and improve
the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current
portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays.
The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
For more information, contact:
Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFO
Website: www.klothoneuro.com.
Forward-Looking Statements:
This press release contains forward-looking statements. These statements
are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking
statements generally are identified by the words "believe," "project," "expect," "anticipate,"
"estimate," "intend," "strategy," "future," "opportunity," "plan," "may,"
"should," "will," "would," "will be," "will continue," "will likely result,"
and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include
descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements
about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many
factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's
inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections
and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors
and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange
Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained
in the forward-looking statements. Copies of these documents are available on the SEC's website, www.sec.gov. All information provided
herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except
as required under applicable law.